Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why Abiomed Dropped Today

By Brian Orelli, PhD - Oct 29, 2020 at 6:08PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Revenue bounces back, but growth is still lacking.

Shares of Abiomed ( ABMD -3.78% ) closed down 10% today after the medical-device maker reported earnings from its second fiscal quarter and muted guidance for the quarter ahead due to the COVID-19 pandemic.

Revenue was up 27% from the first quarter as hospitals opened up and doctors were able to perform procedures to implant Abiomed's Impella heart pumps. While the most recent quarter looked better than the first fiscal quarter, procedure growth is still stymied with Abiomed's revenue up just 2% compared to the same quarter last year. Year-over-year growth outside the U.S. was up 13%, but U.S. sales, which are substantially larger, dragged down overall sales with a decrease of 1% year over year.

Abiomed is still generating operating cash flow and continues to turn a profit to the tune of $62.2 million in the second fiscal quarter. The bottom line was boosted by a gain on its investment in Shockwave Medical and excess tax benefits related to employee share-based compensation awards. But even backing out those two items, the profit was $46.1 million, substantially higher than the $13.1 million Abiomed earned in the year-ago quarter.

Doctor talking to a patient.

Image source: Getty Images.

Unfortunately, Abiomed's management doesn't expect growth to come back anytime soon. In the current quarter, the healthcare company is looking for revenue in the range of $221 million to $230 million, which would be flat to 4% growth compared to the same period last year.

Fortunately for Abiomed and its investors, the patients aren't going to get better on their own, so the company should be able to capture many of the patients who have put off procedures until the pandemic begins to wane.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ABIOMED, Inc. Stock Quote
ABIOMED, Inc.
ABMD
$300.63 (-3.78%) $-11.81
ShockWave Medical Stock Quote
ShockWave Medical
SWAV
$165.13 (-4.29%) $-7.40

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
141%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/04/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.